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The Mycobacterium tuberculosis (Mtb) pathogen encodes a
GlcNAc-6-phosphate deacetylase enzyme, NagA (Rv3332), that
belongs to the amidohydrolase superfamily. NagA enzymes cat-
alyze the deacetylation of GlcNAc-6-phosphate (GlcNAc6P) to
glucosamine-6-phosphate (GlcN6P). NagA is a potential antitu-
bercular drug target because it represents the key enzymatic
step in the generation of essential amino-sugar precursors
required forMtb cell wall biosynthesis and also influences recy-
cling of cell wall peptidoglycan fragments. Here, we report the
structural and functional characterization of NagA fromMyco-
bacterium smegmatis (MSNagA) andMycobacterium marinum
(MMNagA), close relatives ofMtb. Using a combinationofX-ray
crystallography, site-directed mutagenesis, and biochemical
and biophysical assays, we show that these mycobacterial NagA
enzymes are selective for GlcNAc6P. Site-directed mutagenesis
studies revealed crucial roles of conserved residues in the active
site that underpin stereoselective recognition, binding, and
catalysis of substrates.Moreover, we report the crystal structure
of MSNagA in both ligand-free form and in complex with the
GlcNAc6P substrate at 2.6 and 2.0 Å resolutions, respectively.
TheGlcNAc6P complex structure disclosed the precisemode of
GlcNAc6P binding and the structural framework of the active
site, including two divalent metals located in the / binuclear
site. Furthermore, we observed a cysteine residue located on a
flexible loop region that occludes the active site. This cysteine is
unique to mycobacteria and may represent a unique subsite for
targeting mycobacterial NagA enzymes. Our results provide
critical insights into the structural and mechanistic properties
of mycobacterial NagA enzymes having an essential role in ami-
no-sugar and nucleotide metabolism in mycobacteria.
Mycobacterium tuberculosis (Mtb)2 is a major human patho-
gen and is the causative agent of tuberculosis (TB). In 2016,
there were 10.4 million people with new TB infections, and
1.7 million people died of the disease (1). The emergence of
drug-resistant strains ofMtb has resulted in untreatable forms
of TB, and there is therefore an urgent requirement for novel
strategies to address this global health threat. The success of
Mtb as a pathogen is due in part to the complex mycobacterial
cell wall that comprises three distinct macromolecules: pepti-
doglycan (PG), arabinogalactan (AG), and mycolic acids that
form the mAGP complex and is further interspersed with dis-
tinctive lipids and an outermost capsule of polysaccharides and
proteins (2). The cell envelope has been implicated in key roles
in the survival and virulence ofMtb and as such is an important
target for current TB drugs and compounds that are in clinical
development (3).
Glucosamine-6-phosphate (GlcN6P) is an essential amino-
sugar that acts as a gatekeeper between the glycolysis metabolic
pathway and cell wall biosynthesis (Fig. 1) (4). Glucosamine
derivatives are key precursors in the synthesis ofMtb PG found
in the Mtb disaccharide GlcNAc–L-rhamnose, which links
PG3AG (5, 6), and are additionally important inMtb resuscita-
tion pathways (7, 8) and cell wall recycling ofmurein derivatives
(9–13). The isomerization of GlcN6P to glucosamine-1-phos-
phate is the first step ofMtb cell wall biosynthesis (14, 15) (Fig.
1). InMtb GlcN6P can be derived from two biosynthetic path-
ways. Either GlmS (Mtb Rv3436) isomerizes fructose-6-phos-
phate from the glycolysis pathway toGlcN6P (14, 16) orGlcN6P
can be derived from deacetylation of GlcNAc-6-phosphate
(GlcNAc6P) by a putative GlcNAc6P deacetylase enzyme
(NagA), which is assigned to Mtb ORF Rv3332 (NagA) (17).
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Hence, the Mtb GlmS and NagA enzymes have key roles in
controlling the intracellular pools of GlcN6P, and the in vitro
essentiality of both genes has been established in Mtb from
transposon mutagenesis studies (18). In addition, metabolic
profiling of guinea pigs infected with Mtb showed up-regula-
tion of NagA in infected lung tissue (13, 19).
NagA enzymes (EC 3.5.1.25) are widespread in nature and
found in a range of eukaryotic and prokaryotic species (20) as
metal-dependent enzymes with a physiological role in catalyz-
ing the deacetylation of GlcNAc6P to yield GlcN6P and acetate
(Fig. 1) (21–23). A putative catalytic mechanism for NagA
enzymes has been proposed in which nucleophilic attack
occurs via a water/hydroxide ion. Themechanism proceeds via
a strictly conserved active-site aspartic acid residue that has an
essential role in catalysis and is understood to act initially as a
base to activate the hydrolytic water molecule and then as an
acid to protonate the amine leaving group (23–25). High-reso-
lution X-ray structures have been determined of NagA from
three Gram-negative bacteria species: Escherichia coli (PDB
codes 1YMY, 1YRR, 2P50, and 2P53) (21, 23) with and without
a transition state inhibitor (N-methylhydroxyphosphinyl-D-
glucosamine-6-phosphate), Thermotoga maritima (PDB code
1O12), and Vibrio cholerae (PDB 3EGJ and 3IV8); and the
Gram-positive Bacillus subtilis organism (PDB code 2VHL)
with the GlcN6P reaction product (24). All NagA structures
characterized to date reveal a similar overall architecture and
arrangement of two domains. Domain I comprises a (/)8-
barrel structural fold that forms the dimeric interface with
domain I of the neighboring subunit. This dimeric interface
enables the formation of two identical active sites that are
involved in substrate and metal co-factor recognition. The
smaller second domain of NagA enzymes comprises a -barrel
with unknown biological function. There are intriguing differ-
ences in the active site metal-binding site. The NagA enzyme
from E. coli contains a mononuclear metal-binding site (21–
23), whereas the corresponding enzymes fromT. maritima and
from the Gram-positive B. subtilis both have binuclear metal-
binding sites, though in the former case only one metal ion is
necessary for catalysis (22, 24). It is therefore possible that
NagA enzymes have evolved to have a different role or catalytic
function depending on the organism in which they are found.
WithinMtb, NagA (Rv3332) is found in a four-gene operon
also encoding a putative aminotransferase (Rv3329); dacB1
(Rv3330), an enzyme involved in PG maturation; and SugI
(Rv3331), a putative sugar-importer (17, 26) (Fig. 2). Despite its
importance inMtb, detailed studies of NagA from mycobacte-
Figure 1. Schematic diagram of the pathways of amino sugar metabolism inM. tuberculosis. The reaction catalyzed by NagA (GlcNAc6P deacetylase) is
highlighted in red. Glc6P, glucose-6-phosphate; F6P, fructose-6-phosphate; GlcN6P, glucosamine-6-phosphate; GlcN1P, glucosamine-1-phosphate; GlcNAc1P,
GlcNAc-1-phosphate; SugI, integral sugar transporter; Pgi, glucose-6-phosphate isomerase; GlmS, glutamine-fructose-6-phosphate aminotransferase; GlmM,
phosphoglucosamine mutase; GlmU, bifunctional acetyltransferase/uridyltransferase.
NagA frommycobacteria specific for GlcNAc6P
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ria have not yet been reported. This study focuses on the NagA
homologs fromMycobacterium marinum andMycobacterium
smegmatis, close relatives to Mtb. Here, we describe the func-
tional characterization and structural determination of myco-
bacterial NagA enzymes.We report the crystal structure ofWT
and mutantM. smegmatis NagA, both in ligand-free form and
complexed to the GlcNAc6P substrate, revealing themolecular
determinants and structural framework of the active site. Fur-
thermore,wehave carried out site-directedmutagenesis target-
ing putative catalytic residues allowing us to elaborate on the
molecular recognition of NagA indicating the importance of
conserved active-site amino acids in the catalytic function and
substrate and stereochemical requirements of this important
Mtb enzyme.
Results
Production ofMMNagA andMSNagA
To produce recombinant NagA protein, the nagA gene was
amplified by PCR and cloned into either the pET28a plasmid
for co-expression in E. coli containing the Mtb GroES chaper-
one or pYUB1062 (27) for expression in M. smegmatis, both
bearing an N-terminal His6 tag. It proved difficult to obtain
the recombinant Mtb NagA protein, and therefore homo-
logous enzymes from M. marinum and M. smegmatis were
used in these studies, which have a high degree of sequence
identity to the TBNagA enzyme with 71 and 52% sequence
identity, respectively, at the amino acid level (28) (Fig. S1).
Soluble, active MMNagA and MSNagA proteins were
obtained and purified to apparent homogeneity using Co2
affinity, anion exchange, and size-exclusion chromatogra-
phy (Fig. S2 and S3). The identities of the NagA proteins
were confirmed using in-gel trypsin digestion and analysis of
the peptides by MS.
Substrate specificity of MMNagA andMSNagA
NagA enzymes from other species (Fig. S1), are known to
catalyze the deacetylation of GlcNAc6P (20–23), and we there-
fore speculated that mycobacterial NagA enzymes catalyze a
similar reaction. The ability of theMSNagAandMMNagApro-
teins to catalyze the deacetylation of various N-acetyl amino
sugars was tested using a fluorescence-based assay by monitor-
ing the production of the fluorescent product formed from the
reaction of fluorescamine and the free-amino group that is
formed following deacetylation (29). The panel of carbohy-
drates tested is shown in Fig. 3. We first examined the NagA
reaction with various phosphorylated N-acetylated amino sug-
ars that included the predicted GlcNAc6P substrate, alongside
the epimeric analogs GalNAc-6-phosphate (GalNAc6P) and
ManNAc-6-phosphate (ManNAc6P) (Fig. 3). The measure-
ments indicated that MMNagA and MSNagA are active
deacetylase enzymes with markedly similar kinetic profiles
(Table 1). In each case we were able to detect the formation of
GlcN6P, GalN6P, and ManN6P in the reaction, with both
MSNagA and MMNagA showing a clear preference for
the GlcNAc6P substrate (Table 1). Although MSNagA and
MMNagA show activity toward GalNAc6P and ManNAc6P,
kinetic analysis revealed that the Km value was 40-fold higher
for GalNAc6P and 6-fold higher for ManNAc6P than for
GlcNAc6P (Table 1 and Fig. 4). Intriguingly, the apparent
kinetic constants varied for theMSNagA enzyme depending on
whether the protein had been expressed in an E. coli or
M. smegmatis host expression systemwith a higherKm value of
5.2 mM and almost 5-fold reduction in the kcat found for
MSNagA when expressed in E. coli (Table 1).
The importance of the phosphate group in substrate recog-
nition and catalysis was examined through the reaction of
NagA with GlcNAc-6-sulfate (GlcNAc6S) and GlcNAc.
MMNagA andMSNagAwere both able to catalyze the reaction
with GlcNAc6S; however, in both instances the Km values were
7-fold higher (Table 1 and Fig. 4) than the phosphorylated ana-
log. No catalytic activity toward GlcNAc was observed for
either enzyme, indicating the importance of an anionic group at
the 6-position and, in particular, a preference for the phosphate
group for substrate recognition and catalysis. Next, we deter-
mined the importance of the N-acetyl group position at C2
through replacement with an N-glycolyl group, which can be
tolerated by mammalian NagA homologs (30); however, only
low levels of enzymatic activity for both MMNagA and
MSNagA enzymes with this derivative with an extended linker
at the C2 position were observed. Finally, we determined
whether the mycobacterial NagA enzymes could act as a
deacetylase for N-acetyl muramic acid 6-phosphate, which
incorporates a C3 lactoyl group into GlcNAc6P, given that
N-acetyl muramic acid is the main other sugar constituent of
the peptidoglycan backbone. However, no detectable catalytic
activity was observed in this instance indicating selectivity of
mycobacterial NagA enzymes for the GlcNAc6P cell wall pep-
tidoglycan fragment.
Metal dependence of MMNagA andMSNagA
NagA homologs from other organisms require a divalent
metal ion for catalysis (20–23). To further determine the metal
content of MMNagA and MSNagA enzymes, protein samples
were analyzed for the metals: manganese, iron, cobalt, nickel,
copper, zinc, and cadmium using inductively coupled plasma
MS (ICP–MS). From these studies, it was clear that when both
MMNagA and MSNagA enzymes were expressed using an
E. coli expression system in either LBmedium or terrific broth,
Figure 2. The NagA operon inM. tuberculosis. The operon organization was taken from Xbase. The accession numbers for these genes in M. tuberculosis
H37Rv are as follows: Rv3329 (probable aminotransferase), Rv3330 (dacB1, probable penicillin-binding protein D-alanyl-D-alanine carboxypeptidase), Rv3331
(sugI, probable sugar-transport integral membrane protein), and Rv3332 (nagA, GlcNAc-6-phosphate deacetylase).
NagA frommycobacteria specific for GlcNAc6P
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both zinc and iron were the predominant metals and were
found in a1:2 zinc:iron ratio (Table S2). In comparison, when
the MSNagA enzyme is expressed using a M. smegmatis
expression system in LB medium, the protein contained pre-
dominantly more zinc in a 12:1 zinc:iron ratio. These differ-
ences in the selected metal ion that is incorporated into the
protein during protein production may explain the increase in
the Km and reduction in kcat for the MSNagA protein that is
expressed in an E. coli host system (Table 1). Expression of
MSNagA in E. coli in LB medium supplemented with 1 mM
ZnCl2 did not alter the zinc:iron ratio, suggesting that the host
expression system plays a significant role in metal co-factor
selectivity.
CD spectroscopy revealed that removal of the metal ions,
confirmed by ICP–MS, from either enzyme by extensive
dialysis against chelex-treated buffer containing 10 mM 1,10-
phenanthroline and 10 mM EDTA, resulted in unfolding and
loss of catalytic activity (Fig. S4). Activity could not be
restored by addition of ZnCl2 to the metal-free enzymes,
indicating that the metal ions are tightly coordinated in the
active site and have an essential structural role in mycobac-
terial NagA enzymes.
Analysis of the pH dependence of MMNagA andMSNagA
To investigate the pH optimum for NagA catalysis with
GlcNAc6P, the specific activities of the MMNagA and
MSNagA enzymes were determined with GlcNAc6P across a
range of pH values (Fig. S5). This shows the loss of catalytic
activity at a pH below 5.5. The pH profile resembles that found
for the E. coli NagA enzyme (23), where deprotonation of a
catalytic acidic aspartic acid residue is necessary for activity.
Figure 3. Panel of carbohydrates probed in the kinetic studies.
Table 1
Steady-state kinetic parameters of MMNagA andMSNagA
Each assay was carried out in triplicate and is expressed as S.E. —, not detected/no activity.
Enzyme Expression host Substrate Km kcat kcat/Km(mM 103)
mM s1 M1 s1
MMNagA E. coli GlcNAc6P 3.0 0.4 36.8 1.6 12.3 1.7
MMNagA E. coli GalNAc6P 145.4 14.2 5.4 0.3 0.03 0.01
MMNagA E. coli ManNAc6P 19.3 2.1 18.2 0.8 1.1 0.1
MMNagA E. coli GlcNAc6S 20.9 2.4 36.0 1.6 1.7 0.2
MMNagA E. coli GlcNAc — — —
MMNagA E. coli GlcNGc6P — — —
MMNagA E. coli MurNAc6P — — —
MMNagA QXN E. coli GlcNAc6P 26.7 2.7 6.6 0.3 0.3 0.02
MMNagA AXA E. coli GlcNAc6P — — —
MMNagA E127A E. coli GlcNAc6P — — —
MMNagA H139A E. coli GlcNAc6P — — —
MMNagA R225A E. coli GlcNAc6P — — —
MMNagA H249A E. coli GlcNAc6P — — —
MMNagA D272A E. coli GlcNAc6P — — —
MSNagA E. coli GlcNAc6P 5.2 1.0 20.7 1.8 4.0 0.8
MSNagA D267A E. coli GlcNAc6P — — —
MSNagA M. smegmatis GlcNAc6P 3.2 0.4 91.1 5.5 28.0 3.8
MSNagA M. smegmatis GalNAc6P 118.5 10.2 31.1 1.5 0.3 0.03
MSNagA M. smegmatis ManNAc6P 19.1 1.8 70.6 2.5 3.7 0.4
MSNagA M. smegmatis GlcNAc6S 21.4 2.1 33.2 1.3 1.6 0.2
MSNagA M. smegmatis GlcNAc — — —
MSNagA M. smegmatis GlcNGc6P — — —
MSNagA M. smegmatis MurNAc6P — — —
E. coli NagA E. coli GlcNAc6P 5.2 1.1 97.2 5.3 18.7 0.05
NagA frommycobacteria specific for GlcNAc6P
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Site-directedmutagenesis of MMNagA andMSNagA
To assess the significance of selected MMNagA and
MSNagA residues in molecular recognition and function, we
generated single point mutations in five amino acids in
MMNagA, with one corresponding mutation inMSNagA, that
were expected to form either the ligand- ormetal-binding sites.
In addition, we generated two point mutations in the binuclear
metal binding site of the MMNagA enzyme. The HXH motif
(His-56–His-58), also found in B. subtilis and T. maritima
NagA enzymes, wasmutated to either a QXNmotif to replicate
the single metal-binding motif found in both the E. coli and V.
cholerae NagA enzymes, or to AXA. For each mutant, we con-
firmed that the introducedmutationwas not detrimental to the
correct folding of the protein by CD spectroscopy (Fig. S4).
In each case the single amino acid mutation resulted in com-
plete loss of activity of the MMNagA and MSNagA proteins
(Table 1) under the conditions tested, supporting the notion
that these residues have a key influence on substrate selectivity
and/or catalysis. To ensure that the mutation did not result in
reduction/loss of metal ion during expression and/or purifica-
tion, zinc was added to the reaction mixture, but this did not
restore activity. Increasing the concentration of GlcNAc6P
substrate and protein along with the reaction time did result
in the observation of low (5%) residual activity for three
MMNagA mutants: H139A, H249A, and R225A compared
with WT. The QXN and AXA double mutants in the second
metal-binding site motif resulted in protein that, although cor-
rectly folded, was inherently less stable. However, catalytic
activity for the MMNagA QXN mutant with GlcNAc6P was
observed, with a 7-fold increase inKm value comparedwithWT
MMNagA (Table 1). In contrast, no activity was detected for
the AXA MMNagA mutant with GlcNAc6P. Despite these
mutations in the active site of MMNagA and MSNagA being
detrimental for the catalytic activity of these enzymes, the
mutants were still able to bind and recognize the GlcNAc6P
substrate, as evidenced from microscale thermophoresis
(MST) studies (Table S3).
Overall structure of MSNagA
To determine the molecular mechanism and structural basis
of catalysis, we solved the crystal structure ofMSNagAwith and
without the GlcNAc6P substrate present. The MSNagA pro-
tein in the absence of ligand crystallized in space group P1 with
four molecules in the asymmetric unit. Phases for the structure
of ligand-freeMSNagAwere determined bymolecular replace-
ment using the structure of E. coli NagA (PDB code 2P50) as a
search model, and the structure was refined at a resolution of
2.6 Å. To investigate the interaction of the GlcNAc6P substrate
with the protein, we mutated Asp-267, which has been shown
to be important for catalysis in otherNagA enzymes (21–24), to
alanine. This resulted in significant loss of enzymatic activity
(Table 1) and enabled co-crystallization of the MSNagA
enzyme in the presence of GlcNAc6P. The crystals grew under
identical conditions to the native protein with crystals in space
group C2. The structure was solved by molecular replacement
using the apo-MSNagA as amodel and refined at a resolution of
2.0 Å. The refined structures have Rwork values of 24.7% (apo;
PDB code 6FV3) and 18.4% (ligand-bound; PDB code 6FV4),
with Rfree values of 29.5 and 23.7% respectively. Statistics of the
Figure4. SubstratedependenceofMMNagAactivity.Michaelis–Menten curveswere fitted, and selected curves are shown forMMNagAwith the substrates
GlcNAc6P (A), GalNAc6P (B), ManNAc6P (C), and GlcNAc6S (D). The initial velocity data were plotted against the substrate concentration, and each assay was
carried out in triplicate and expressed as a value standard error of mean.
NagA frommycobacteria specific for GlcNAc6P
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diffraction data and structure refinement are summarized in
Table 2.
Overall, the structure of MSNagA is very similar to other
NagA enzymes with NagA from E. coli, the closest structural
match according to PDBeFOLD (31), aligning with a rootmean
square deviation of 1.4 Å for 334 aligned residues (target resi-
dues, 354; sequence identity, 35%; PDB code 3IV8). The struc-
ture can be divided into two domains. Domain I (residues
52–344) is a twisted (/)8-TIM barrel that is comprised of
eight alternating -stands and -helices and encloses the cata-
lytic site of the enzyme and themetal-binding site. Domain II is
a small -barrel comprising eight -strands contributed
from the N and C termini of the MSNagA protein (amino
acids 1–51 and 344–382) (Fig. 5). In both of the MSNagA
crystal structures, the protein forms a homodimer (Fig. 5)
burying a total of 3,200 Å2 of the surface area (32). By com-
parison to the determined crystal structures of NagA en-
zymes, this dimeric interaction is similar across bacterial
NagA enzymes (21, 22, 24). The two active sites of the
MSNagA homodimer are formed at the interface of domain I
between the two monomeric subunits (Fig. 5) with hydrogen
bonding between residues on 8 and 9 and salt bridges
between Glu-230 and Arg-251. A long flexible loop formed
from residues 203–223 of one subunit extends out to 9 of its
neighboring subunit (residues 248–258), providing addi-
tional stability at the dimer interface. In solution, MMNagA
andMSNagA are found as dimers as shown by size exclusion
chromatography (Figs. S2 and S3), and it is likely that this
dimeric oligomerization state is also the biologically relevant
unit for mycobacterial homologs, which has been found for
other NagA enzymes (21, 22, 24, 33).
The ligand-binding site of MSNagA
From our MST studies (Table S3) the D267A MSNagA
mutant was still able to interact with the GlcNAc6P substrate,
although no catalytic activity was observed (Table 1). The co-
crystal structure shows clear electron density for GlcNAc6P in
the substrate-binding pocket of ChainA, enabling the substrate
to be modeled in the active-site pocket at the dimeric interface
(Fig. 6 and Fig. S6). However, it may be that the site is not fully
occupied, and no electron density for the GlcNAc6P substrate
was observed in the second active site of chain B where instead
a flexible loop region from Glu-122 to Pro-136 partially
occludes the active site (Fig. S7). The reasons for these differ-
ences between the equivalent active sites in the co-crystallized
complex are not clear; however, it is intriguing that a similar
situation is also observed in the co-crystal structure of the
enzyme from B. subtilis with the GlcN6P reaction product,
where only partial occupancy (0.3) was observed in the sec-
ond binding pocket (24).
The GlcNAc6P substrate is situated in the cavity of the (/)
barrel of domain I at the dimer interface, recruiting Arg-219
from the opposing monomer through an interaction with the
phosphate moiety. An arginine at this position is specific to
MSNagA and in both M. marinum and Mtb NagA homologs
the equivalent residue is replaced by a histidine residue (Fig.
S1). The side chain of the conserved arginine residue corre-
sponding to Arg-220 in MSNagA points away from the
GlcNAc6P ligand (Fig. S8).
TheGlcNAc6P substrate is found in the-configuration and
is anchored in place through the formation of hydrogen bonds
Table 2
Crystallographic parameters for theMSNagA andGlcNAc6P–MSNagA
complex
apo-MSNagA GlcNAc6P–MSNagA
PDB ID 6FV3 6FV4
Data collection
Beamline Diamond I04 Diamond I24
Wavelength (Å) 0.9795 0.9686
Space group P1 C2
Unit cell parameters
a (Å) 60.45 164.76
b (Å) 86.39 54.43
c (Å) 89.93 110.26
 (°) 88.12 90.00
 (°) 75.58 123.22
 (°) 69.79 90.00
Molecules in ASU 4 2
Resolution, (outer shell) (Å)a 55–2.58
(2.62–2.58)
80.14–1.97
(2.08–1.97)
Unique reflections 51,044 (3,798) 55,882 (8,181)
Multiplicity 2.6 (2.7) 6.5 (6.30)
CC1/2 0.960 (0.434) 0.993 (0.841)
Completeness (%)a 98.2 (98.0) 96.8 (98.1)
Rmerge (%)a 17.3 (90.2) 12.8 (82.2)
Mean I/(I)a 4.3 (1.0) 9.1 (2.7)
Refinement
Rwork (%) 24.7 18.4
Rfree (%) 29.5 23.7
r.m.s.d.
Bond lengths (Å) 0.005 0.007
Bond angles (°) 1.0 0.91
No. of nonhydrogen atoms
Protein atoms 10,714 5,513
Ligand/ions 8 35
Solvent waters 333 530
Average B factors (Å2)
Overall 42.7 37.4
Protein 42.9 36.9
Ligand/ions 40.7 46.7
Solvent 34.5 42.1
Ramachandran plotb
Favored region (%) 94.3 96.33
Allowed region (%) 4.75 3.2
Outer region (%) 0.95 0.39
a The numbers in parentheses refer to the highest-resolution shell.
b Ramachandran plot statistics were calculated by MolProbity.
Figure 5. Crystal structure of MSNagA. Shown is MSNagA structure with
one subunit (chain A) represented as a cartoon and the other subunit (chain
B) with surface representation. Domain I is colored blue, and domain II is
colored brown (chain A)/red (chain B)). Themetal ions are represented as gray
spheres, and the GlcNAc6P ligand is shown in stick representation.
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with the side chains of His-244 that interacts with the anomeric
GlcNAc6P hydroxyl group and with Asn-212 to the phosphate
group. The remaining hydrogen bonds are through interactions
with the main chain, with the equatorial C3-hydroxy group
interacting with Ala-133 and the equatorial C4-hydroxy with
Ile-301. These critical residues that interact withGlcNAc6P are
conserved in homologous NagA enzymes with the exception of
Ile-301 (MSNagA), which is instead replaced by a leucine resi-
due; however, this modification is unlikely to affect its interac-
tion to the substrate with the interaction occurring through its
backbone carbonyl group. Additional interactions of the phos-
phate group are with the backbone amino group of Ala-213 and
the guanidine group of Arg-219 from the opposing molecule
(Fig. 6).
The carbonyl group of the GlcNAc6P substrate is positioned
2.5 Å from the M1 metal ion, which is ideally primed to sta-
bilize the transition state intermediate formed during catalysis
(Fig. 6). It is of interest to note, by comparison of the apo-
and ligand-bound structures, that there is little conforma-
tional change in the binding pocket upon substrate binding
to MSNagA. However, there is a difference in two loop re-
gions that impact on the accessibility of the active site. The
surface-based loop that comprises the amino acids Met-
274–Ser-304 forms a dynamic “lid” that is likely to be func-
tionally important in facilitating ligand binding through an
opening/closing mechanism. An additional loop that differs
between the two structures, comprising residues Glu-122–
Pro-136, partially occludes the active site in chain B and
prevents substrate binding (Fig. S7). Although domain II is
not involved in substrate binding, we do observe a change in
the position of the -barrel in chains A and B of the ligand-
bound structure.
Binding ofmetal ions toMSNagA
Although no divalent cations were added during the purifi-
cation steps, well defined electrondensity corresponding to two
Figure 6. TheGlcNAc6P substrate-binding site inMSNagA.A, illustration showingGlcNAc6Pwith green carbon atoms, themetal ion as a pale-yellow sphere,
and selectedaminoacid residues in stick representation (coloredgray for chainA, andmagenta for chainB).B, schematicdiagramof the interactionsofMSNagA
withGlcNAc6P. The residues that interactwith theM1metal are shown in green, the residues that interactwith theM2metal are shown in red, the residues that
interact with the GlcNAc6P substrate are shown in black, the residues that interact with the GlcNAc6P substrate from the opposing MSNagA monomer are
shown in blue, and the Asp-267 residue that is mutated in the ligand-bound structure is shown in purple.
NagA frommycobacteria specific for GlcNAc6P
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bound metal ions was clearly visible in the cavity of the (/)
barrel buried at the bottom of the active-site cleft (Fig. 7). Each
MSNagA monomer in both the ligand-free and ligand-bound
models contains two metal ions positioned between 3.1 and
3.4 Å apart from each other. The proteins were shown to
contain both zinc and iron in the ICP–MS analysis (Table
S2). Given that the same protein expressed in M. smegmatis
contains predominantly zinc, it was decided to model the
metal-binding sites as zinc rather than iron (see “Experimen-
tal procedures”; Fig. S9). However, for the ligand-bound
mutant structure, residual density in the M1metal-ion bind-
ing site indicated a larger ion. We therefore modeled a cad-
mium ion at this position, which is likely to arise as a result of
the addition of CdCl2 in the crystallization conditions with
the metal-binding site perhaps being destabilized by the
D267A mutation.
All of the ligands that interact with the metal ions are con-
tributed by conserved residues from one subunit of the dimer.
In all chains of the apo-structure, the metal ion that is more
buried (M1) makes four interactions coordinated by the side
chains His-56, His-58, Glu-122, and Asp-267 (Fig. 7). The sec-
ond metal ion (M2) is held in position by the side chains of
residuesHis-188,Glu-122, andHis-209 (Fig. 7). Coordination is
completed by water molecules with one water molecule mod-
eled as bridging both of themetals and another bound toM1. In
the ligand-bound structure, thewatermolecule that bridges the
two metal ions in the apo-structure is instead replaced with a
chloride ion. The coordination of the metal ions in chain A to
His-56, His-58, and Glu-122 is almost identical to that of the
apo-structure with loss of coordination occurring to the Asp-
267 residue, which has instead beenmutated to an alanine. The
M2metal ion is similarly coordinated to Glu-122, His-188, and
His-209, and it is striking that an additional interaction is
formed with the carbonyl group of the GlcNAc6P substrate,
replacing the water molecule in the apo-structure. The second
chain of the co-crystal structure, where there is no GlcNAc6P
substrate, can also be considered as another view of the apo-
structure. Here there is a translational movement of His-134,
which is located within the Glu-122–Pro-136 loop that blocks
the active site, such that the histidine side-chain is 2.6 Å from
the cadmium ion (Fig. 7). In the ligand-bound structure, this
histidine residue is within 3 Å of the carbonyl oxygen of the
substrate. This histidine is important in catalysis because its
mutation in MMNagA (His-139) results in loss of activity
(Table 1).
Discussion
In prokaryotic species, it has been demonstrated thatNagA is
involved in the deacetylation of GlcNAc6P with an important
role in carbohydrate metabolism and the recycling of murein
fragments from the cell wall (11, 12, 34). A putative NagA
enzyme, organized in an operon that differs from other bacte-
rial organisms, has been identified inMtb through genomic and
proteomic studies and is predicted to be essential in the Mtb
pathogen (17–19). Our biochemical and structural analyses of
mycobacterial NagA enzymes are an important step to under-
standing amino-sugar assimilation, recycling, and metabolism
inMtb.
Our X-ray crystallographic structure determination reveals
that MSNagA conforms to the urease structural superfamily,
with the same overall fold, domain topology, and architecture
as other NagA enzymes whose structures have been deter-
mined (21, 22, 24). MSNagA comprises two domains with for-
mation of the active-site binding pocket occurring within
domain I of the enzyme. Recruitment of a nonconserved Arg-
219 from domain I from the adjacent monomer explains the
dimeric nature of the enzyme. It is noteworthy that the myco-
bacterial NagA enzymes also form functional dimers. Mapping
of Arg-219 to TBNagA reveals that this residue is instead
replaced by a histidine residue, and it is probable that the
invariant TBNagA arginine residue (Arg-220 MSNagA, cor-
responding to Arg-225 MMNagA and Arg-221 TBNagA) is
utilized, along with the adjacent histidine residue that facil-
itates additional interactions with the 6-phosphate group of
GlcNAc6P in a similar pincer manner to that of B. subtilis
NagA (24). Modification of Arg-225 in MMNagA resulted in
loss of catalytic function, indicating the important func-
tional role of this conserved residue. Domain II appears to
have no role in substrate binding, and the biological role of
this small -barrel/sandwich domain remains unclear. Our
attempts to investigate the role of the -barrel domain of
MSNagA through the generation of a truncation mutant was
hindered by the loss of production of soluble recombinant
protein and suggests that the -barrel domain has a role in
the stability of MSNagA.
Figure7.Structureof themetal-bindingsiteofMSNagA.A, illustration showingmetal-binding site inapo-MSNagAstructure (chainA,magenta) superposed
with ligand-bound structure (chain A, blue). Silver spheres, Zn2; red spheres, H2O. GlcNAc6P with green carbon atoms and selected amino acid residues are
shown in stick representation (colored by apo (magenta) or ligand-bound (blue)). B, superposition of the metal-binding site of chain A and chain B of the
ligand-bound structure. Light blue, chain A; light brown, chain B; silver spheres, Zn2; orange sphere, Cd2; green sphere, Cl. Selected amino acid residues are
shown in stick representation (colored by chain A (blue) or ligand-bound (salmon)).
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Importantly, in these studies we are able to unambigu-
ously determine the position and orientation of the carbonyl
group of GlcNAc6P, which is displaced in the NagA catalytic
reaction. The binding mode of the biological GlcNAc6P sub-
strate with MSNagA is very similar to that identified in the
structure of B. subtilis NagA in complex with the GlcN6P
product (24) and an E. coli NagA catalytically inactive
mutant in complex with a N-methlhydroxyphosphinyl-D-
glucosamine-6-phosphate transition state inhibitor (22).
TheMSNagA complex structure indicates that the active site
does not undergo anymajor structural change on binding the
GlcNAc6P substrate; however, two loop regions demonstrate a
capacity for conformational flexibility and an importance in
facilitation of substrate binding. A notable difference between
mycobacterial NagA enzymes and NagA enzymes from other
bacterial species is the presence of a cysteine at position 131
(MSNagA), which is replaced by a corresponding lysine residue
in nonmycobacterial species and is located in the flexible loop
that precludes the physiological substrate from binding. On the
basis of the significant variation of a noncatalytic cysteine
located within a region linked with substrate binding, there is
the potential to exploit this reactive sulfhydryl moiety with the
view to designing inhibitors specific for the TBNagA enzyme. A
recent example of a cysteine-targeted therapeutic approach is
in the development of irreversible peptidomimetic inhibitors to
a noncatalytic cysteine located in the hepatitis C virus protease
(35).
Our kinetic analysis reveals that MMNagA and MSNagA
enzymes catalyze the deacetylation of the amino-sugar
GlcNAc6P to form GlcN6P and acetate. Biochemical charac-
terization has provided the first evidence of the function
of mycobacterial NagA enzymes and demonstrated that
MMNagA and MSNagA have comparable kinetic profiles to
each other, and the kinetic constants reported here for
MSNagA and MMNagA are comparable with the E. coli NagA
enzyme in our fluorescent assay. The presence of a binuclear
metal-binding site and two divalent metal ions located in each
active site of MSNagA, which are both required for efficient
catalysis and structural stability, is comparable with the Gram-
positive NagA homolog and substantiates evidence that NagA
enzymes have diverged with an evolutionary adaption that
enables the mechanism of activation and stabilization of the
carbonyl intermediate to differ depending on themetal require-
ments of the specific organism.
From the extensive panel of carbohydrates tested in this
study, there was a clear preference of MMNagA and MSNagA
for GlcNAc6P over the epimeric amino-sugar analogs
ManNAc6P and GalNAc6P, indicating that the mycobacterial
NagA enzymes are sensitive to the stereochemical require-
ments of the substituent at the C2 and C4 of the substrate.
Although there is a clear preference for an equatorial N-acetyl
group at C2, an axial C2 N-acetyl group, in the case of
ManNAc6P, can bemoderately tolerated. In contrast, there is a
highly stringent selection for the equatorial C4 hydroxyl group
of GlcNAc6P, with a marked reduction in the catalytic effi-
ciency kcat and an increase in the observed Km for GalNAc6P,
where the C4 hydroxy group is positioned in an axial confor-
mation. This was also observed for the E. coli NagA enzyme
with the epimeric GalNAc6P substrate (23). Furthermore, the
presence of a phosphate group at C6 is required for efficient
catalysis to proceed. The biochemical results are consistent
with the crystal structure of the complex and reveal that myco-
bacterial NagA enzymes are fine-tuned with a precise binding
network that allows for the specific recognition and catalysis of
the GlcNAc6P amino-sugar. Mammalian species have the abil-
ity to accommodate the largerN-glycolyl group ofN-glycolylg-
lucosamine-6-phosphate and deacetylate the acetyl and glyco-
lyl GlcN6P analogs with equivalent efficiency (30). However,
our studies demonstrate that mycobacterial NagA enzymes are
distinct from these mammalian deacetylase enzymes and do
not have this capacity to tolerate the introduction of a larger
glycolyl group at the C2 position, indicating that mycobacterial
NagA enzymes have evolved to have unique specificity and
function.
The stringent recognition of themurein fragmentGlcNAc6P
over N-acetyl muramic acid 6-phosphate by mycobacterial
NagA enzymes is interesting andmay occur to ensure the integ-
rity of Mtb peptidoglycan recycling and amino-sugar metabo-
lism.Mtb nagA is encoded along with genes involved in pepti-
doglycan biosynthesis and carbohydrate uptake (Fig. 2) (17, 26),
indicating theMtbNagA is primed to play a role in the recycling
of GlcNAc6P derived from the breakdown of cell-wall pepti-
doglycan. NagA has been shown to be involved in amino-sugar
acquisition and peptidoglycan recycling in a number of other
organisms including E. coli (36) (11), B. subtilis (37), Staphylo-
coccus aureus (38), and Streptomyces coelicolor (34, 39).Hydrol-
ysis ofMtb peptidoglycan is mediated through lytic transglyco-
sylase resuscitation factors (40), and it is likely that Mtb has
evolved functional pathways to enable the recovery of murein
fragments within the nutrient poor macrophage environment.
TheMtb solute-binding protein UspC of the UspABC trans-
porter has recently been shown to be involved in the recog-
nition of amino sugars with a potential role in recycling
deacetylated PG fragments (41). Intriguingly, Mtb lacks the
genetic machinery for phosphotransferase systems, and
given the genomic organization of nagA, it is tantalizing to
link the functional role of the Mtb SugI transporter to the
import of phosphorylated carbohydrates, which subse-
quently acts in concert with the deactylase NagA enzyme to
recycle and optimize the use of restricted carbohydrates dur-
ing intracellular infection.
In conclusion, the NagA enzymes from M. smegmatis and
M. marinum, with high sequence identity to theM. tuberculo-
sis analog, are the first NagA enzymes to have been character-
ized both structurally and kinetically frommycobacteria. Given
that there is almost identical sequence identity of these
enzymes with the active-site of TBNagA, these mycobacterial
homologs represent good model systems to understand the
NagA enzyme from Mtb. Our data clearly indicate that myco-
bacterial NagA enzymes have a clear substrate preference for
GlcNAc6P and other amino-sugar derivatives are poorly toler-
ated. Eukaryotic NagA enzymes convert GlcNAc6P directly to
GlcNAc-1-phosphate, have low sequence identity (34%) to
TBNagA, and differ in substrate selectivity. In this context, the
conversion ofGlcNAc6P toGlcN6P bymycobacterial NagA is a
bacterial specific process that occurs at an essential metabolic
NagA frommycobacteria specific for GlcNAc6P
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chokepoint in the GlcN6P degradation pathway. Given the
importance of TBNagA enzymes in the synthesis of essential
mycobacterial cell wall components, TBNagA may serve as a
novel molecular drug target, and these studies provide a frame-
work to exploit this enzyme in the search for new TB therapeu-
tic agents.
Experimental procedures
Materials and reagents
All chemicals and reagents were purchased from Sigma–
Aldrich, unless specified, with the exception of all of the carbo-
hydrates used in this study, which were purchased fromCarbo-
synth. PCR and restriction enzymes were obtained from New
England Biolabs. Double-distilled water was used throughout.
Plasmid constructs, protein expression, and purification
Full-length GlcNAc-6-phosphate deacetylase (nagA) genes
from M. tuberculosis, M. marinum, and M. smegmatis were
amplified by PCR from the corresponding gDNA. The primer
sequences are listed inTable S1. The PCRproductswere ligated
into either NdeI andHindIII sites of the pET28a () (Novagen)
for expression in E. coli or pYUB1062 (27) for expression inM.
smegmatis mc24517, resulting in the constructs TBnagA_
pet28a, MMnagA_pet28a, MSnagA_pet28a, and MSnagA_
pYUB1062. Targeted single-site or double-site substitutions
were introduced into MMnagA_pet28a and MSnagA_pet28a
using the primers (Table S1), with Phusion Polymerase and the
PCR cycle (98 °C, 30 s; 25 cycles of 98 °C, 10 s; 60 °C, 30 s; 72 °C,
4 min; followed by 5 min at 72 °C), followed by digestion with 1
l of DpnI. Plasmid sequences were verified by sequencing
(GATC) and used for protein expression.
Protein expression of NagA in E. coli
E. coli BL21(DE3) competent cells were co-transformedwith
the appropriate nagA_pet28a expression plasmid and the
GroES 60.2 Mtb chaperone and grown at 27 °C to an optical
density at 600 nm (A600) of 0.5 in terrific broth medium (Difco)
supplemented with 50 g ml1 kanamycin and 100 g ml1
ampicillin. Protein production was induced with 0.5 mM iso-
propyl--thiogalactopyranoside, and the cultures were grown
at 16 °C overnight with shaking (180 rpm). The cells were har-
vested (4,000 g, 30 min, 4 °C) and resuspended in lysis buffer
(20 mM Tris, 300 mM NaCl, 10% glycerol, pH 8.0 (buffer A))
supplemented with 0.1% Triton X-100 and frozen at 80 °C
until further use.
Protein expression of NagA inM. smegmatis
M. smegmatis mc24517 electrocompetent cells were trans-
formed with the appropriate nagA_pYUB1062 construct and
grown at 37 °C to an A600 value of 0.8 in LB medium supple-
mented with 0.05% Tween 80, 0.2% glycerol, 25 g ml1 kana-
mycin, and 100 g ml1 hygromycin. Protein production was
induced with 0.2% acetamide, and the cultures were grown at
37 °C for an additional 20 h with shaking (180 rpm). The cells
were harvested and resuspended in lysis buffer (buffer A) sup-
plemented with 0.1% Triton X-100 and frozen at 80 °C until
further use.
Protein purification
Complete protease inhibitormixture (Pierce), 5mMMgCl2, 2
mg of DNase, and 20 mg of lysozyme were added to the resus-
pended pellet, and the pellet was either sonicated (E. coli pel-
lets) on ice (Sonicator Ultrasonic Liquid Processor XL; Miso-
nix) or passed through a cell disruptor at 4 °C (M. smegmatis
pellets) (Constant Systems, 25 kpsi). Following centrifugation
(27,000 g, 40 min, 4 °C) the supernatant was filtered (0.45-m
pore size) and loaded onto a pre-equilibrated HisPur Co2-
affinity resin (Thermo Scientific, Pierce). The column was
washedwith bufferA (5 columnvolumes), and the recombinant
NagA protein was eluted from the Co2 resin with increasing
concentrations of imidazole. Fractions containing the protein
were dialyzed at 4 °C for 12 h against buffer A, and either a
second HisPur Co2-affinity resin purification step was under-
taken or fractions containing NagA protein were dialyzed
against 20 mM Tris-HCl, 100 mM NaCl, 10% glycerol pH 8.0
(buffer B) at 4 °C for 12 h and applied to a HiTrap Q-column (1
ml; GEHealthcare Life Sciences) pre-equilibrated with buffer B
and eluted with NaCl (0.1–1 M). Fractions containing NagA
were pooled and purified further using size exclusion chroma-
tography. Gel filtration experiments were carried out on a
Superdex 200 16/60 column (GEHealthcare) using 20mMTris,
300mMNaCl, 10% glycerol, pH 8.0. Fractions containing NagA
were pooled, 0.03% DDM and 1 mM DTT were added, and the
protein was concentrated to 5–10 mg/ml (Vivaspin 2; GE
Healthcare) and stored at80 °C. The identity of the proteins
was confirmed by tryptic digest and nanoLC–electrospray ion-
ization–MS/MS (WPH Proteomics Facility, University of
Warwick).
NagA assay
Concentrated MSNagA and MMNagA enzymes were dia-
lyzed into 20 mM Bis-Tris, 300 mM NaCl, 10% glycerol, pH 7.0.
The E. coli NagA enzyme was commercially available and
obtained from NZYtech. The activity of the NagA enzyme was
measured at 37 °C in an end point assay by following the pro-
duction of the fluorescent product formed with fluorescamine
and primary amines at ex of 340 nm and em of 460 nm. Unless
otherwise stated, the reaction was carried out in a 96-well
microtiter plate in 20 mM Bis-Tris, 300 mMNaCl, 10% glycerol,
pH 7.0, in a total reaction volume of 50 l. The reaction was
initiated by the addition of substrate and terminated by the
addition of 50 l of 0.4 M borate buffer pH 10, 40 l of 5 mM
fluorescamine, and 50 l of dimethylformamide to label the
free amines and the production of fluorescence was monitored
at ex of 340 nm and em of 460 nm (Tecan InfiniteM200). The
production of free amine was quantified with a glucosamine
standard. For characterization of the kinetics ofNagA substrate
initial utilization rates of NagA catalysis were obtained. Kinetic
parameters were calculated and analyzed using nonlinear
regression analysis (GraphPad Prism, v7). All measurements
were performed in triplicate. The impact of pH on activity was
determined at 37 °C in the pH range 4.0 to 9.0 with GlcNAc6P
(5 mM concentration). The following buffers were used: phos-
phate-citrate buffer, 300 mM NaCl, 10% glycerol (pH 4.0–7.0),
20 mM Bis-Tris, 300 mM NaCl, 10% glycerol (pH 6.0–7.0), and
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20 mM Bis-Tris propane, 300 mM NaCl, 10% glycerol (pH
6.0–9.0).
Affinity studies withMST
NagAproteinwas labeled usingMonolithHis-tag labeling kit
RED–Tris–nickel–nitrilotriacetic acid in 50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 10 mM MgCl2, 0.05% Tween 20, and a con-
stant concentration of NagA (50 nM) was used. Carbohydrates
were prepared in water in the concentration range 0–0.5 M.
The samples were loaded into the MonoLite NT.115 standard
treated capillaries and incubated for 10 min before analysis
using the Monolith NT.115 instrument (NanoTemper Tech-
nologies) at 21 °C using 40% laser power and 20% LED power.
The binding affinities were calculated with GraphPad Prism
software. All experiments were carried out in triplicate.
Circular dichroism
Purified NagA proteins (0.3 mg/ml) were dialyzed in 20 mM
Tris, 100mMNaCl, 10% glycerol, pH 8.0 buffer, transferred into
a 1-mmpath-length quartz cuvette, and analyzed on Jasco J-810
DC spectrometer from 198 to 260 nm. The spectra were
acquired in triplicate and averaged after subtraction of the
buffer background.
Inductively coupled plasmaMS (ICP–MS)
NagA proteins were diluted into 72% ultrapure HNO3 and
heated to 70 °C for 30 min and then diluted with MilliQ deion-
ized water to give a final concentration of 2%HNO3. Themetal
contents of the NagA samples were determined by ICP–MS
(Agilent ICP–MS 7500cx) and by comparison to solutions of
known metal concentrations using external calibration stan-
dards, which were prepared through a serial dilution of a single
ppm stock mixture of zinc, cadmium, cobalt, copper, manga-
nese, nickel, and iron in 2% nitric acid. External standards were
prepared at 1, 2.5, 5, 10, 25, 50, 100, 250, 500, and 1,000 ppb. The
masses of the isotopes detected were 55Mn, 57Fe, 59Co, 63Cu,
60Ni, 66Zn, and 111Cd. 166Er was used as an internal standard.
Operating conditions were: plasma gas flow rate, 15.0 liters/
min; auxiliary gas flow rate, 0.15 liter/min; nebulizer flow rate,
0.808 rps; and RF power, 1,550 W.
Crystallization and structure determination
Crystals of NagA were grown initially by vapor diffusion in
96-well plates (Swiss-Ci), using aMosquito liquid handling sys-
tem (TTP LabTech) by mixing 1:2 volumes (150 nl) of concen-
trated NagA (10 mg/ml) with reservoir solution. NagA crystals
grew within a week at 22 °C in 0.12 M monosaccharide mix
(Morpheus, Molecular Dimensions), 0.1 M imidazole/MES, pH
6.5, 20% (v/v) PEG 500 MME, 10% (w/v) PEG 20,000 with the
addition of 10 mMCdCl2 additive. For co-crystallization exper-
iments, the D267A MSNagA was incubated with 5 mM
GlcNAc6P and incubated at 4 °C for 30 min before crystalliza-
tion in the same reservoir conditions. Crystals were flash frozen
in liquid nitrogen prior to data collection.
Structure determination
The X-ray diffraction data for both apo- and ligand-bound
MSNagA crystals were collected at I04 and I24 beamlines of
Diamond Light Source, respectively. Apo-MSNagA diffraction
data were indexed, integrated, and scaled with XDS (42)
through theXIA2pipeline and theCCP4 suite of programs (43).
Initial phases were obtained by molecular replacement using
PHASER (44) with the NagA structure from E. coli (PDB code
2P50, chain A) as a search model. AutoBuild (45) was initially
used for themodel building followed by iterative cycles of alter-
nating manual rebuilding in COOT (46), and reciprocal space
crystallographic refinement with PHENIX-REFINE (47). The
electron density in one of the flexible loop region (residues
275–300) was very weak, and the model building in this region
was donemanually in O (48). The ligand-boundMSNagA crys-
tal data were also indexed, integrated, and scaled with XDS (42)
through the autoPROC (49) pipeline. Initial phases were
obtained by molecular replacement using PHASER (44) with
the structure of the apoMSNagA (Chain A) as a search model,
and the structurewas refined as per the apoMSNagA.A feature
enhanced 2Fo  Fc map (fem map) was calculated to enhance
the fine details of the ligand density and the GlcNAc6P ligand
was fitted into the electron densitymap. TheGradeWeb server
(Global Phasing Ltd., http://grade.globalphasing.org/cgi-bin/
grade/server.cgi)3 was used for the ligand restraint generation
and optimization. The conformation of the GlcNAc6P ligand
was validated with Privateer (50). The occupancy of the refined
ligand was set at 0.75 because the associated density suggested
that the site was not fully occupied. At this resolution it is dif-
ficult to distinguish zinc and iron ions in the electron density.
Based on the ICP–MS results, we decided to model the metal
ions as zinc. This resulted in B-factors of the metal ions similar
to those of the surrounding residues. For one metal site in the
D267A ligand-bound MSNagA structure, the residual density
suggested amore electron-rich ion, and therefore cadmiumwas
modeled at this position. In both the apo- and ligand-bound
MSNagA structures, the interacting distances between the
amino acids and the zinc ion at the active site were restrained to
2.1 Å, whereas no such restraints were applied to the cadmium
ion interactions. Noncrystallographic symmetry restraints
were initially used during refinement cycles; however, these
were not used in the final refinements. Because of the higher
resolution of ligand-boundMSNagA, it was used as a reference
model for generating dihedral angles restraints during the
refinement of apo-MSNagA.
The model of the apo-MSNagA structure determined com-
prises residues 1–377 in all chains (A–D), with an additional
two residues defined (1–379) in chain B. MSNagA is a 385-
amino acid protein, and clear density for the final C-terminal
residues was not observed. The first residue of the partially
ordered N-terminal His6 tag can also be observed in chains
A–D. In the apo-MSNagA structure, there is one disordered
region in chainDbetween residues 276 and 302. In chainsA–C,
weak electron density for this region was observed, indicating
that this loop region of MSNagA is flexible. In comparison, the
ligand-bound GlcNAc6P–MSNagA complex structure resi-
dues 1–378 (chain A) and residues 1–382 (chain B) are well
defined by their electrondensitymaps, enabling the positions of
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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these amino acid residues to be determined with an additional
three residues of the N-terminal His6-tag linker observed in
both chains. Structure validations were done by MolProbity
(51).
In the Ramachandran plot of the ligand-bound structure,
there is only one serious outlier per chain. This is for His-209,
one of themetal ligands. This residue forms part of a-turn and
coordinates Zn1. Phe-211, which is on the margin of the
allowed zone is also in this region. The density is unambiguous
in this region, and the homologs in the PDB file have similar
outliers. In the apo-structure, some of the residues in the flex-
ible loops are on themargins of the allowed regions in the Ram-
achandran plot (see above). The figures were drawn using
PyMOL (PyMOL Molecular Graphics System, version 2.0;
Schrödinger), except those showing electron density, which
were made using CCP4 mg (52).
Synthesis
NMR spectroscopy (1H, 13C) was conducted on either a
Bruker DPX-300 or Bruker DPX-400 spectrometer, and all
chemical shifts () are given in ppm relative to the solvent ref-
erence. The data are recorded as follows: chemical shift (multi-
plicity (s for singlet, d for doublet, t for triplet, m for multiplet,
and br for broad), coupling constant(s) J are quoted in Hz).
Mass spectroscopy was obtained using a Bruker HCT Ultra
machine. TLCs were performed on Merck silica gel 60 F-254
TLC sheets and were visualized by staining with 10% H2SO4 in
ethanol followed by heating. Flash chromatographywas carried
out using Sigma–Aldrich technical grade silica gel (pore size, 60
Å; particle size, 40–63 m) as the stationary phase.
N-Glycolylglucosamine-6-phosphate
Glucosamine-6-phosphate (200 mg, 0.772 mmol), glycolic
acid (59mg, 0.772mmol), benzotriazol-1-yl-oxytripyrrolidino-
phosphoniumhexafluorophosphate (483mg, 0.926mmol), and
triethylamine (222 l, 1.54 mmol) were dissolved in dimethyl-
formamide (50 ml) and MilliQ water (5 ml), and the reaction
mixture was stirred at room temperature for 16 h. The reaction
mixture was concentrated in vacuo, re-dissolved in water (30
ml), and extracted with chloroform (3  30 ml). The aqueous
phase was separated and concentrated in vacuo. The solid res-
idue was subsequently suspended in THF (50 ml), filtered, and
then washed with THF (5  5 ml), chloroform (5  5 ml),
acetone (5 5 ml), and methanol (5 5 ml). The residue was
then dissolved in water (20 ml), acidified to pH 1.0 (0.1 M HCl),
and concentrated in vacuo. The solid residue was suspended in
THF (50 ml), filtered, and washed with chloroform (5 5 ml),
acetone (5  5 ml), and ethanol (5  5 ml). The residue was
then dissolved in water and concentrated in vacuo to give a
brown solid (70mg, 33%): 1HNMR (400MHz, D2O): ppm 5.15
(1H, d, J 2.5 Hz, C1H -anomer), 4.89 (1H, d, J 8.0 Hz, C1H
-anomer), 4.06 (2H, s, C OCH2), 3.41–4.17 (6H, m, C2–5H
andC6H2). 13CNMR (75MHz,D2O): ppm175.5, 175.0 (CO),
94.7 (C1H -anomer), 90.0 (C1H -anomer), 74.6, 73.4, 70.5,
70.4, 69.5, 69.4 (C3–5H), 64.3, 60.8 (C6H2), 55.2, 56.2 (C2H), 44.6
(COCH2). 31P NMR (121 MHz, D2O): ppm 0.45.m/z (ES)
C8H15NO10P expected 316.0439, found 316.0438 [M-H].
Chemoenzymatic synthesis of N-acetyl muramic acid
6-phosphate
Clostidium acetobutylicum MurK was overexpressed and
purified as described previously (53). The enzymatic reaction
contained N-acetyl muramic acid (50 mM), ATP (67 mM),
MgCl2 (10 mM), and MurK (10 g) in 50 mM Tris-HCl, pH 8.0,
and was incubated at 37 °C for 7 h. The product was purified by
silica column chromatography (5:4:2:1 n-butanol/methanol/
ammonium hydroxide 35%/H2O) to give the product as a white
solid (63 mg). 1H NMR (400 MHz, D2O) ppm: 5.47 (1H maj, br
s, anomeric CH), 4.65 (1H min, d, J  9.0 Hz, anomeric CH),
4.40 (1Hmaj, q, J 7.0 Hz, CHCH3), 4.23 (1Hmin, m, CHCH3),
3.46–4.13 (5H maj 5H min, m, sugar ring), 2.00 (3H, s, C
OCH3), 1.28–1.35 (3H,m,CHCH3). 13CNMR (100MHz,D2O)
-anomer: ppm181.8 (C O), 174.4 (C O), 95.7, 90.0, 80.1,
78.6, 78.2, 76.7, 72.0, 71.0, 63.4, 62.5, 55.8, 54.2 (sugar ring 
CHCH3), 22.0 (C  OCH3), 18.7 (CHCH3). 31P NMR (161
MHz, D2O) ppm 1.66. m/z (ES) C11H19NO11P expected
372.0701, found 372.0703 [M-H].
Accession codes
Coordinates and structure factors for MSNagA have been
deposited in the ProteinData Bank under accession codes 6FV3
for the ligand-free MSNagA structure and 6FV4 for the
GlcNAc6P-MSNagA co-crystal structure.
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